NCT01909934 2025-09-19Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaTakedaPhase 4 Completed50 enrolled 22 charts
NCT01396070 2017-04-05Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelStanford UniversityPhase 2 Completed36 enrolled 13 charts
NCT00866047 2017-03-22A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaSeagen Inc.Phase 2 Completed58 enrolled 19 charts
NCT00947856 2017-02-02A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudySeagen Inc.Phase 2 Completed110 enrolled 15 charts
NCT01421667 2016-11-28A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaSeagen Inc.Phase 2 Completed176 enrolled 30 charts
NCT00365274 2014-06-02SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaNational Cancer Institute (NCI)Phase 2 Terminated6 enrolled 3 charts